"OP0216 EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, June 2017." by Philip Mease

Presentation

OP0216 EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, June 2017.

The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology (2017)

Philip Mease, Providence St. Joseph Health
et.al.

Link

Disciplines

Rheumatology

Publication Date

June, 2017

Citation Information

Philip Mease and et.al.. "OP0216 EFFICACY AND SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): A RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, June 2017." The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology (2017)
Available at: http://works.bepress.com/philip-mease/239/